Decreasing trends of allo-HCT over the last decade (A) and duration of response of patients after CAR T (red) and after polatuzumab followed by allo-HCT (blue). (A) Decreasing trend of Utilization of Allogeneic Transplant in DLBCL provided by the Center for International Blood and Marrow Transplant Research (CIBMTR), (B) Swimmers Plot reporting duration of response after CAR T-cell therapy and after allo-HCT by subject.